loader from loading.io

In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more

Diabetes Connections | Type 1 Diabetes

Release Date: 03/24/2026

Four Tubeless Pumps in 2027?! CGM studies in older people, new T1D insurance tool, ADA controversy continues, and more! show art Four Tubeless Pumps in 2027?! CGM studies in older people, new T1D insurance tool, ADA controversy continues, and more!

Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections In the News… two new tubeless pumps are cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA  Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns.. Check out all of Announcing Community Commericals! Learn how to  Learn more about  Please visit our Sponsors & Partners - they help make the show possible!  from extreme temperatures The best way to keep up with...

info_outline
Finding Diabetes Joy: How Poetry Helped Ephraim Navigate a T1D Diagnosis show art Finding Diabetes Joy: How Poetry Helped Ephraim Navigate a T1D Diagnosis

Diabetes Connections | Type 1 Diabetes

In this bonus episode of Diabetes Connections, meet Ephraim Sommers, an English professor and poet diagnosed with LADA (a slower-developing form of type 1 diabetes) in his early 40s. Even though his father has type 1, Ephraim wasn't prepared for the fear, anxiety, and mental load of managing diabetes himself. So he turned to poetry. Every weekday, he sat in a coffee shop and wrote about gratitude. Those poems became about finding joy while living with diabetes. We talk about shifting from fear to gratitude, advocating for yourself, and why poetry might help even if you haven't read a poem...

info_outline
Can a 100-Old Vaccine Impact Type 1 Diabetes?  A Conversation with Dr. Denise Faustman show art Can a 100-Old Vaccine Impact Type 1 Diabetes? A Conversation with Dr. Denise Faustman

Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections - looking into a very old vaccine to get new results for people with type 1. Dr. Denise Faustman’s research into the BCG vaccine has been making headlines for a long time, and she's now sharing new results from her clinical trials, including some pretty remarkable claims about A1C, insulin use, and time in range. Now, I know some of you may be surprised that I'm having Dr. Faustman on the show. She's a very controversial figure in the diabetes research world, and her work has sparked plenty of debate and skepticism over the years. We're not ignoring any of...

info_outline
In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more show art In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more

Diabetes Connections | Type 1 Diabetes

  This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that’s completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for sports on the highest level with type 1. And it’s diabetes awareness momth! It’s all coming up right after this. (AD BREAK) Welcome! I’m your host Stacey Simms and this is...

info_outline
What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill show art What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill

Diabetes Connections | Type 1 Diabetes

What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes. I’m talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care. We also talk about how even the...

info_outline
Meet GLUKI, the T1D App Helping Kids Learn Through Play show art Meet GLUKI, the T1D App Helping Kids Learn Through Play

Diabetes Connections | Type 1 Diabetes

On this bonus episode of diabetes connections.. the creator o designed to help kids understand diabetes through games, rewards, and interactive learning. I’m talking to Staci DePatie who lives with type 1.  Staci's working with students at UC Irvine to bring Gluki to life, including some interesting new AI features. We'll talk about how it all works, why she believes building what she calls "diabetes IQ" is so important, and I'll ask some questions about AI safety, cost, and whether kids really want to spend more time thinking about diabetes, even if it’s as part of a game. This...

info_outline
In the News.. Dexcom controversy, New T1D research, and a World Series moment to remember! show art In the News.. Dexcom controversy, New T1D research, and a World Series moment to remember!

Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response  New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series! Check out all of Announcing Community Commericals! Learn how to  Learn...

info_outline
Sernova + Seraxis: A New Partnership in the  Race for a T1D Cure with CEOs  Johnathan Rigby and Dr. Will Rust show art Sernova + Seraxis: A New Partnership in the Race for a T1D Cure with CEOs Johnathan Rigby and Dr. Will Rust

Diabetes Connections | Type 1 Diabetes

A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes. So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1? I'm talking with the CEOs...

info_outline
What's Next for Dexcom?  G8, New Research & Your Questions with Jessica Castle, VP Global Medical Affairs show art What's Next for Dexcom? G8, New Research & Your Questions with Jessica Castle, VP Global Medical Affairs

Diabetes Connections | Type 1 Diabetes

On this bonus episode of Diabetes Connections, catching up with Dexcom after the EASD  international conference. I’m asking your questions about longer sensor wear for kids, changes to adhesive, what’s going on with the G8 and more.  Plus Dexcom presented a few studies at the summer conferences about some pretty significant benefits of CGM, including fewer DKA-related hospital visits for people with type 1 and improved glucose outcomes for people with type 2 who aren't using insulin. This podcast is not meant at medical advice, if you have those types of questions, please ask...

info_outline
In the News... Experimental new peptide for T2D, low-carb studies in kids, GLP-1 pill info, gaps in CGM access, fashion line honors a T1D icon, and more! show art In the News... Experimental new peptide for T2D, low-carb studies in kids, GLP-1 pill info, gaps in CGM access, fashion line honors a T1D icon, and more!

Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections In the News… A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2. Plus, new data on Lilly’s daily GLP-1...

info_outline
 
More Episodes

It's In the News, a look at the top headlines and stories in the diabetes community.

This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more!

Announcing Community Commericals! Learn how to get your message on the show here.

Learn more about studies and research at Thrivable here

Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 

transcript with links: 

Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

Who’s in Vegas? I’ll see you there at the Breakthrough T1D summit this weekend.

And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more.

Okay.. our top story this week:

XX

Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication.

It’s one of the leading causes of vision loss in the US and many other western countries.

These researchers now say a clinical trial is the next step.

https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/

XX

new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes.

Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes.

However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.

 

https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk

XX

Researchers in Japan say they’ve developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor.

The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice’s blood sugar was reduced to near-normal levels.

Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed.

https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests

 

XX

 

Lilly says it’s next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight.

Retatrutide also met the study’s second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight.

The company was also “very pleased” with the relatively low discontinuation rates due to side effects, which were up to 5%, he added.

But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year.

Still, retatrutide’s A1C reduction doesn’t appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients.

Dubbed the “triple G” drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person’s appetite and satisfaction with food than other treatments.

 

https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html

XX

 

The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It’s about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott.

MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0.

MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes.

https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html

 

XX

Lots of new out of the recent ATTD conference.. some headlines:

New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year.

--

The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells.

--

Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.

 

Researchers noted that the body’s response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows.

--

More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.

 

Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.

 

Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85.

https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026

 

XX

Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it’s the world’s first fully closed loop commercial launch.

CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife’s (formerly Ypsomed Diabetes Care’s) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device.

https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/

XX

Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes.

The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy.

Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027.

Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.

 

https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/

XX

Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.